New perspectives regarding β 2-adrenoceptor ligands in the treatment of asthma

British Journal of Pharmacology

Volumn 163, Issue 1, 2011, Pages 18-28

  Walker, J K L ^a   Penn, R B ^b   Hanania, N A ^c   Dickey, B F ^d   Bond, R A ^e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF HOUSTON   (United States)

Author keywords

2 adrenoceptor; agonist; asthma; biased agonism; constitutive activity; efficacy; inverse agonist

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; ALLERGEN; ANGIOTENSIN 2 RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ARRESTIN; CARVEDILOL; CYCLIC AMP DEPENDENT PROTEIN KINASE; FENOTEROL; FORMOTEROL; G PROTEIN COUPLED RECEPTOR; ISOPRENALINE; LIGAND; METOPROLOL; METOPROLOL TARTRATE; MUCIN; NADOLOL; PLACEBO; SALBUTAMOL; SALMETEROL;

ASTHMA; DESENSITIZATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME ACTIVATION; ENZYME ACTIVITY; EPITHELIUM CELL; HEART FAILURE; HEART PROTECTION; HUMAN; METAPLASIA; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANIMALS; ASTHMA; HUMANS; LIGANDS; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 79953724848     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01178.x     Document Type: Review

References (96)

1. Ariens E, (1954). Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems and theory. Arch Int Pharmacodyn Ther 99: 32-49.
2. Arunlakshana O, Schild HO, (1959). Some quantitative uses of drug antagonists. Br J Pharmacol 14: 48-58.
3. Attramadal H, Arriza JL, Aoki C, Dawson TM, Codina J, Kwatra MM, et al,. (1992). Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene family. J Biol Chem 267: 17882-17890.
4. Baillie GS, Sood A, McPhee I, Gall I, Perry SJ, Lefkowitz RJ, et al,. (2003). β-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates β-adrenoceptor switching from Gs to Gi. Proc Natl Acad Sci USA 100: 940-945. (Pubitemid 36183934)
5. Bateman E, Nelson H, Bousquet J, Kral K, Sutton L, Ortega H, et al,. (2008). Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med 149: 33-42.
6. Benovic JL, Pike LJ, Cerione RA, Staniszewski C, Yoshimasa T, Codina J, et al,. (1985). Phosphorylation of the mammalian beta-adrenergic receptor by cyclic AMP-dependent protein kinase. Regulation of the rate of receptor phosphorylation and dephosphorylation by agonist occupancy and effects on coupling of the receptor to the stimulatory guanine nucleotide regulatory protein. J Biol Chem 260: 7094-7101. (Pubitemid 15016102)
7. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP, (1998). Effector pathway-dependent relative efficacy at serotonin Type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54: 94-104. (Pubitemid 28337591)
8. Billington C, Penn R, (2003). Signaling and regulation of G protein-coupled receptors in airway smooth muscle. Respir Res 4: 2.
9. Bohn LM, Gainetdinov RR, Lin F-T, Lefkowitz RJ, Caron MG, (2000). [mu]-Opioid receptor desensitization by [beta]-arrestin-2 determines morphine tolerance but not dependence. Nature 408: 720-723. (Pubitemid 32015987)
10. Bond RA, Ijzerman AP, (2006). Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol Sci 27: 92-96. (Pubitemid 43184030)
11. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, et al,. (1982). Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N Engl J Med 307: 205-211. (Pubitemid 12079105)
12. Callaerts-Vegh Z, Evans KLJ, Dudekula N, Cuba D, Knoll BJ, Callaerts PFK, et al,. (2004). Effects of acute and chronic administration of β-adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci USA 101: 4948-4953. (Pubitemid 38469183)
13. Carman CV, Parent J-L, Day PW, Pronin AN, Sternweis PM, Wedegaertner PB, et al,. (1999). Selective regulation of Gαq/11 by an RGS domain in the G protein-coupled receptor kinase, GRK2. J Biol Chem 274: 34483-34492. (Pubitemid 129511796)
14. Castle W, Fuller R, Hall J, Palmer J, (1993). Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. Br Med J 306: 1034-1037. (Pubitemid 23105961)
15. Chidiac P, Hebert TE, Valiquette M, Dennis M, Bouvier M, (1994). Inverse agonist activity of beta-adrenergic antagonists. Mol Pharmacol 45: 490-499. (Pubitemid 24094939)
16. Clark AJ, (1933). The Mode of Action of Drugs on Cells. E Arnold & Company: London.
17. Clark AJ, (1937). General Pharmacology. Supplement, 4th edn. Julius Springer: Berlin.
18. Costa T, Herz A, (1989). Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 86: 7321-7325. (Pubitemid 19254452)
19. Delavoie F, Molinari M, Milliot M, Zahm J-M, Coraux C, Michel J, et al,. (2009). Salmeterol restores secretory functions in cystic fibrosis airway submucosal gland serous cells. Am J Respir Cell Mol Biol 40: 388-397.
20. Dennis SM, Sharp SJ, Vickers MR, Frost CD, Crompton GK, Barnes PJ, et al,. (2000). Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Lancet 355: 1675-1679. (Pubitemid 30248479)
21. Deshpande DA, Penn RB, (2006). Targeting G protein-coupled receptor signaling in asthma. Cell Signal 18: 2105-2120. (Pubitemid 44636173)
22. Deshpande DA, Theriot BS, Penn RB, Walker JKL, (2008). {beta}-Arrestins specifically constrain {beta}2-adrenergic receptor signaling and function in airway smooth muscle. FASEB J 22: 2134-2141. (Pubitemid 351948632)
23. Drake MT, Violin JD, Whalen EJ, Wisler JW, Shenoy SK, Lefkowitz RJ, (2008). β-Arrestin-biased Agonism at the β2-Adrenergic Receptor. J Biol Chem 283: 5669-5676.
24. Drazen JM, Israel E, Boushey HA, Chinchilli VM, Fahy JV, Fish JE, et al,. (1996). Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. N Engl J Med 335: 841-847. (Pubitemid 26304065)
25. Druey K, (2009). Regulation of G-protein-coupled signaling pathways in allergic inflammation. Immunol Res 43: 62-76.
26. Evans BA, Sato M, Sarwar M, Hutchinson DS, Summers RJ, (2010). Ligand-directed signalling at β-adrenoceptors. Br J Pharmacol 159: 1022-1038.
27. Finney PA, Belvisi MG, Donnelly LE, Chuang T-T, Mak JCW, Scorer C, et al,. (2000). Albuterol-induced downregulation of Gsα accounts for pulmonary β2-adrenoceptor desensitization in vivo. J Clin Invest 106: 125-135. (Pubitemid 30437248)
28. Furchgott RF, (1966). The use of beta-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor agonist complexes. Adv Drug Res 3: 21-56.
29. Futamura K, Orihara K, Hashimoto N, Morita H, Fukuda S, Sagara H, et al,. (2010). beta2-Adrenoceptor agonists enhance cytokine-induced release of thymic stromal lymphopoietin by lung tissue cells. Int Arch Allergy Immunol 152: 353-361.
30. Gesty-Palmer D, Chen M, Reiter E, Ahn S, Nelson CD, Wang S, et al,. (2006). Distinct β-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem 281: 10856-10864. (Pubitemid 43855508)
31. Gesty-Palmer D, Flannery P, Yuan L, Corsino L, Spurney R, Lefkowitz RJ, et al,. (2009). A β-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med 1 (1 1ra1): 1-9.
32. Grove A, Lipworth BJ, (1995). Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 346: 201-206.
33. Guo M, Pascual RM, Wang S, Fontana MF, Valancius CA, Panettieri RA, et al,. (2005). Cytokines regulate beta-2-adrenergic receptor responsiveness in airway smooth muscle via multiple PKA- and EP2 receptor-dependent mechanisms. Biochemistry 44: 13771-13782. (Pubitemid 41507458)
34. Hanania NA, Singh S, El-Wali R, Flashner M, Franklin AE, Garner WJ, et al,. (2008). The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther 21: 134-141.
35. Hanania NA, Mannava B, Franklin AE, Lipworth BJ, Williamson PA, Garner WJ, et al,. (2010). Response to salbutamol in patients with mild asthma treated with nadolol. Eur Respir J 36: 963-965.
36. Hansen G, Jin S-LC, Umetsu DT, Conti M, (2000). Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. Proc Natl Acad Sci USA 97: 6751-6756. (Pubitemid 30412786)
37. Iaccarino G, Tomhave ED, Lefkowitz RJ, Koch WJ, (1998). Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by ?-Adrenergic receptor stimulation and blockade. Circulation 98: 1783-1789. (Pubitemid 28492500)
38. Investigators B-BEoST (2001). A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344: 1659-1667.
39. Kamachi A, Munakata M, Nasuhara Y, Nishimura M, Ohtsuka Y, Amishima M, et al,. (2001). Enhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol in a rat model of atopic asthma. Thorax 56: 19-24. (Pubitemid 32041714)
40. Kenakin T, (1995a). Agonist-receptor efficacy I: mechanisms of efficacy and receptor promiscuity. Trends Pharmacol Sci 16: 188-192.
41. Kenakin T, (1995b). Agonist-receptor efficacy II: agonist trafficking of receptor signals. Trends Pharmacol Sci 16: 232-238.
42. Kjelsberg MA, Cotecchia S, Ostrowski J, Caron MG, Lefkowitz RJ, (1992). Constitutive activation of the alpha 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. J Biol Chem 267: 1430-1433.
43. Kong KC, Gandhi U, Martin TJ, Anz CB, Yan H, Misior AM, et al,. (2008). Endogenous Gs-coupled receptors in smooth muscle exhibit differential susceptibility to GRK2/3-mediated desensitizationâ. Biochemistry 47: 9279-9288.
44. Laporte SA, Oakley RH, Holt JA, Barak LS, Caron MG, (2000). The interaction of β-arrestin with the AP-2 adaptor is required for the clustering of β2-adrenergic receptor into clathrin-coated Pits. J Biol Chem 275: 23120-23126. (Pubitemid 30646204)
45. Lee TW, Cotecchia S, Milligan G, (1997). Up-regulation of the levels of expression and function of a constitutively active mutant of the hamster alpha1B-adrenoceptor by ligands that act as inverse agonists. Biochem J 325: 733-739.
46. Lefkowitz RJ, Whalen EJ, (2004). [beta]-arrestins: traffic cops of cell signaling. Curr Opin Cell Biol 16: 162-168. (Pubitemid 38757292)
47. Leikauf GD, Ueki IF, Nadel JA, (1984). Autonomic regulation of viscoelasticity of cat tracheal gland secretions. J Appl Physiol 56: 426-430. (Pubitemid 14142861)
48. Lin R, Peng H, Nguyen LP, Dudekula NB, Shardonofsky F, Knoll BJ, et al,. (2008). Changes in [beta]2-adrenoceptor and other signaling proteins produced by chronic administration of ['][beta]-blockers' in a murine asthma model. Pulm Pharmacol Ther 21: 115-124.
49. Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RJ, (1990). β-arrestin: a protein that regulates β-adrenergic receptor function. Science 248: 1547-1550.
50. Loza MJ, Peters SP, Foster S, Khan IU, Penn RB, (2007). [beta]-Agonist enhances type 2 T-cell survival and accumulation. J Allergy Clin Immunol 119: 235-244. (Pubitemid 46037809)
51. Loza MJ, Foster S, Peters SP, Penn RB, (2008). Interactive effects of steroids and beta-agonists on accumulation of type 2 T cells. J Allergy Clin Immunol 121: 750 e751-755 e753.
52. Luttrell LM, Ferguson SS, nbsp G, Daaka Y, Miller WE, et al,. (1999). Beta-arrestin-dependent formation of 2 adrenergic receptor-src protein kinase complexes. Science 283: 655-661.
53. McGraw DW, Forbes SL, Kramer LA, Witte DP, Fortner CN, Paul RJ, et al,. (1999). Transgenic overexpression of β2-adrenergic receptors in airway smooth muscle alters myocyte function and ablates bronchial hyperreactivity. J Biol Chem 274: 32241-32247.
54. McGraw DW, Almoosa KF, Paul RJ, Kobilka BK, Liggett SB, (2003). Antithetic regulation by β-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway β-agonist paradox. J Clin Invest 112: 619-626. (Pubitemid 38056346)
55. McGraw DW, Elwing JM, Fogel KM, Wang WCH, Glinka CB, Mihlbachler KA, et al,. (2007). Crosstalk between Gi and Gq/Gs pathways in airway smooth muscle regulates bronchial contractility and relaxation. J Clin Invest 117: 1391-1398. (Pubitemid 46718427)
56. Milligan G, (2003). Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective. Mol Pharmacol 64: 1271-1276. (Pubitemid 37532215)
57. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, (2006). The salmeterol multicenter asthma research trial. Chest 129: 15-26.
58. Newnham DM, McDevitt DG, Lipworth BJ, (1994). Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. Am J Med 97: 29-37. (Pubitemid 24223631)
59. Newnham DM, Grove A, McDevitt DG, Lipworth BJ, (1995). Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax 50: 497-504.
60. Nguyen LP, Omoluabi O, Parra S, Frieske JM, Clement C, Ammar-Aouchiche Z, et al,. (2008). Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol 38: 256-262. (Pubitemid 351567693)
61. Nguyen LP, Lin R, Parra S, Omoluabi O, Hanania NA, Tuvim MJ, et al,. (2009). β2-Adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. Proc Natl Acad Sci USA 106: 2435-2440.
62. Nishimura K, Tamaoki J, Isono K, Aoshiba K, Nagai A, (2002). β-adrenergic receptor-mediated growth of human airway epithelial cell lines. Eur Respir J 20: 353-358.
63. Ortega VE, Peters SP, (2010). Beta-2 adrenergic agonists: focus on safety and benefits versus risks. Curr Opin Pharmacol 10: 246-253.
64. Parma J, Duprez L, Sande JV, Cochaux P, Gervy C, Mockel J, et al,. (1993). Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365: 649-651. (Pubitemid 23350535)
65. Patel PA, Tilley DG, Rockman HA, (2009). Physiologic and cardiac roles of [beta]-arrestins. J Mol Cell Cardiol 46: 300-308.
66. Pearce N, Beasley R, Crane J, Burgess C, Jackson R, (1995). End of the New Zealand asthma mortality epidemic. Lancet 345: 41-44.
67. Penn R, (2008). Embracing emerging paradigms of G protein-coupled receptor agonism and signaling to address airway smooth muscle pathobiology in asthma. Naunyn Schmiedebergs Arch Pharmacol 378: 149-169.
68. Penn RB, Benovic JL, (2008). Regulation of heterotrimeric G protein signaling in airway smooth muscle. Proc Am Thorac Soc 5: 47-57.
69. Penn RB, Pascual RM, Kim Y-M, Mundell SJ, Krymskaya VP, Panettieri RA, et al,. (2001). Arrestin specificity for G protein-coupled receptors in human airway smooth muscle. J Biol Chem 276: 32648-32656.
70. Petrofski JA, Koch WJ, (2003). The [beta]-adrenergic receptor kinase in heart failure. J Mol Cell Cardiol 35: 1167-1174. (Pubitemid 37163522)
71. Pitcher JA, Freedman NJ, Lefkowitz RJ, (1998). G protein-coupled receptor kinases. Annu Rev Biochem 67: 653-692. (Pubitemid 28411141)
72. Poole-Wilson PA, Swedberg K, Cleland JGF, Di Lenarda A, Hanrath P, Komajda M, et al,. (2003). Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362: 7-13. (Pubitemid 36835815)
73. Rajagopal S, Rajagopal K, Lefkowitz RJ, (2010). Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 9: 373-386.
74. Remington TL, Digiovine B, (2005). Long-acting beta-agonists: anti-inflammatory properties and synergy with corticosteroids in asthma. Curr Opin Pulm Med 11: 74-78. (Pubitemid 40189255)
75. Riesenfeld E, Sullivan M, Thompson-Figueroa J, Haverkamp H, Lundblad L, Bates J, et al,. (2010). Inhaled salmeterol and/or fluticasone alters structure/function in a murine model of allergic airways disease. Respir Res 11: 22.
76. Salpeter S, Buckley N, Ormiston T, Salpeter E, (2006). Meta-analysis: effect of long-acting {beta}-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 144: 904-912. (Pubitemid 46768131)
77. Sayers I, Swan C, Hall IP, (2006). The effect of [beta]2-adrenoceptor agonists on phospholipase C (beta1) signalling in human airway smooth muscle cells. Eur J Pharmacol 531: 9-12. (Pubitemid 43202208)
78. Sears MR, (2002). Adverse effects of [beta]-agonists. J Allergy Clin Immunol 110 (Part 2): S322-S328.
79. Seifert R, Wenzel-Seifert K, (2002). Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmacol 366: 381-416. (Pubitemid 35251788)
80. Shenoy SK, Lefkowitz RJ, (2005). Receptor-specific ubiquitination of β-arrestin directs assembly and targeting of seven-transmembrane receptor signalosomes. J Biol Chem 280: 15315-15324. (Pubitemid 40562888)
81. Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, Madabushi S, et al,. (2006). β-arrestin-dependent, G protein-independent ERK1/2 activation by the β2 adrenergic receptor. J Biol Chem 281: 1261-1273.
82. Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, et al,. (1992). The use of β-agonists and the risk of death and near death from asthma. N Engl J Med 326: 501-506.
83. Srinivasan S, Lubrano-Berthelier C, Govaerts C, Picard F, Santiago P, Conklin BR, et al,. (2004). Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans. J Clin Invest 114: 1158-1164. (Pubitemid 39578705)
84. Stephenson RP, (1956). A modification of receptor theory. Br J Pharmacol Chemother 11: 379-393.
85. Stolley PD, Schinnar R, (1978). Association between asthma mortality and isoproterenol aerosols: a review. Prev Med 7: 519-538. (Pubitemid 9113632)
86. Tamaoki J, Tagaya E, Kawatani K, Nakata J, Endo Y, Nagai A, (2004). Airway mucosal thickening and bronchial hyperresponsiveness induced by inhaled β2-agonist in mice. Chest 126: 205-212. (Pubitemid 38943139)
87. Tao Y-X, (2008). Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics. Pharmacol Ther 120: 129-148.
88. Taylor DR, (2009). The {beta}-agonist saga and its clinical relevance: on and on it goes. Am J Respir Crit Care Med 179: 976-978.
89. Terwilliger RZ, Ortiz J, Guitart X, Nestler EJ, (1994). Chronic morphine administration increases β-adrenergic receptor kinase (βARK) Levels in the rat locus coeruleus. J Neurochem 63: 1983-1986. (Pubitemid 24326247)
90. Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P, (2000). Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 106: 253-262. (Pubitemid 30483129)
91. Violin JD, Lefkowitz RJ, (2007). [beta]-Arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci 28: 416-422.
92. Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, et al,. (2010). Selectively engaging β-arrestins at the AT1R reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 335: 572-579.
93. Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT, Ahn S, et al,. (2007). A unique mechanism of β-blocker action: carvedilol stimulates β-arrestin signaling. Proc Natl Acad Sci USA 104: 16657-16662. (Pubitemid 350211072)
94. Xiao R-P, Zhang S-J, Chakir K, Avdonin P, Zhu W, Bond RA, et al,. (2003). Enhanced Gi signaling selectively negates {beta}2-adrenergic receptor (AR)- but not {beta}1-AR-mediated positive inotropic effect in myocytes from failing rat hearts. Circulation 108: 1633-1639. (Pubitemid 37187792)
95. Yamaki K, Takahashi Y, Sakuragi S, Matsubara K, (1987). Molecular cloning of the S-antigen cDNA from bovine retina. Biochem Biophys Res Commun 142: 904-910. (Pubitemid 17021118)
96. Zhou B, Comeau MR, Smedt TD, Liggitt HD, Dahl ME, Lewis DB, et al,. (2005). Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat Immunol 6: 1047-1053. (Pubitemid 41486190)